249 related articles for article (PubMed ID: 7560726)
1. Tear protein profiles vs. clinical characteristics of untreated and cyclosporine-treated canine KCS.
Fullard RJ; Kaswan RM; Bounous DI; Hirsh SG
J Am Optom Assoc; 1995 Jul; 66(7):397-404. PubMed ID: 7560726
[TBL] [Abstract][Full Text] [Related]
2. Effect of cyclosporine on conjunctival mucin in a canine keratoconjunctivitis sicca model.
Moore CP; McHugh JB; Thorne JG; Phillips TE
Invest Ophthalmol Vis Sci; 2001 Mar; 42(3):653-9. PubMed ID: 11222523
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of pimecrolimus eye drops for treatment of canine keratoconjunctivitis sicca: a comparison with cyclosporine A.
Ofri R; Lambrou GN; Allgoewer I; Graenitz U; Pena TM; Spiess BM; Latour E
Vet J; 2009 Jan; 179(1):70-7. PubMed ID: 17950639
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of 1% cyclosporine for topical treatment of keratoconjunctivitis sicca in dogs.
Olivero DK; Davidson MG; English RV; Nasisse MP; Jamieson VE; Gerig TM
J Am Vet Med Assoc; 1991 Oct; 199(8):1039-42. PubMed ID: 1748606
[TBL] [Abstract][Full Text] [Related]
5. The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca: the effect of topical Cyclosporin A therapy.
Gao J; Schwalb TA; Addeo JV; Ghosn CR; Stern ME
Cornea; 1998 Nov; 17(6):654-63. PubMed ID: 9820947
[TBL] [Abstract][Full Text] [Related]
6. Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca.
Berdoulay A; English RV; Nadelstein B
Vet Ophthalmol; 2005; 8(4):225-32. PubMed ID: 16008701
[TBL] [Abstract][Full Text] [Related]
7. Clinical and light microscopic studies of the conjunctival tissues of dogs with bilateral keratoconjunctivitis sicca before and after treatment with topical 2% cyclosporine.
Izci C; Celik I; Alkan F; Erol M; Sur E
Biotech Histochem; 2015 Apr; 90(3):223-30. PubMed ID: 25747049
[TBL] [Abstract][Full Text] [Related]
8. Use of episcleral cyclosporine implants in dogs with keratoconjunctivitis sicca: pilot study.
Barachetti L; Rampazzo A; Mortellaro CM; Scevola S; Gilger BC
Vet Ophthalmol; 2015 May; 18(3):234-41. PubMed ID: 24799029
[TBL] [Abstract][Full Text] [Related]
9. Topical administration of cyclosporine for treatment of keratoconjunctivitis sicca in dogs.
Morgan RV; Abrams KL
J Am Vet Med Assoc; 1991 Oct; 199(8):1043-6. PubMed ID: 1748607
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes.
Brignole F; Pisella PJ; Goldschild M; De Saint Jean M; Goguel A; Baudouin C
Invest Ophthalmol Vis Sci; 2000 May; 41(6):1356-63. PubMed ID: 10798650
[TBL] [Abstract][Full Text] [Related]
11. Severe, unilateral, unresponsive keratoconjunctivitis sicca in 16 juvenile Yorkshire Terriers.
Herrera HD; Weichsler N; Gómez JR; de Jalón JA
Vet Ophthalmol; 2007; 10(5):285-8. PubMed ID: 17760706
[TBL] [Abstract][Full Text] [Related]
12. A comparative approach to topical cyclosporine therapy.
Williams DL
Eye (Lond); 1997; 11 ( Pt 4)():453-64. PubMed ID: 9425407
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of topical nerve growth factor treatment in dogs affected by dry eye.
Coassin M; Lambiase A; Costa N; De Gregorio A; Sgrulletta R; Sacchetti M; Aloe L; Bonini S
Graefes Arch Clin Exp Ophthalmol; 2005 Feb; 243(2):151-5. PubMed ID: 15650854
[TBL] [Abstract][Full Text] [Related]
14. Assessment of corneal and conjunctival metaplasia by impression cytology during the treatment of canine keratoconjunctivitis sicca.
Radziejewski K; Balicki I; Szadkowski M
Acta Vet Hung; 2018 Jun; 66(2):189-203. PubMed ID: 29958527
[TBL] [Abstract][Full Text] [Related]
15. Histologic characteristics and local cellular immunity of the gland of the third eyelid after topical ophthalmic administration of 2% cyclosporine for treatment of dogs with keratoconjunctivitis sicca.
Izci C; Celik I; Alkan F; Ogurtan Z; Ceylan C; Sur E; Ozkan Y
Am J Vet Res; 2002 May; 63(5):688-94. PubMed ID: 12013470
[TBL] [Abstract][Full Text] [Related]
16. The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs.
Murphy CJ; Bentley E; Miller PE; McIntyre K; Leatherberry G; Dubielzig R; Giuliano E; Moore CP; Phillips TE; Smith PB; Prescott E; Miller JM; Thomas P; Scagliotti R; Esson D; Gadek T; O'Neill CA
Invest Ophthalmol Vis Sci; 2011 May; 52(6):3174-80. PubMed ID: 21330663
[TBL] [Abstract][Full Text] [Related]
17. Spontaneous canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops.
Kaswan RL; Salisbury MA; Ward DA
Arch Ophthalmol; 1989 Aug; 107(8):1210-6. PubMed ID: 2757551
[TBL] [Abstract][Full Text] [Related]
18. Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients.
Lee HK; Ryu IH; Seo KY; Hong S; Kim HC; Kim EK
Ophthalmology; 2006 Feb; 113(2):198-205. PubMed ID: 16360211
[TBL] [Abstract][Full Text] [Related]
19. Assessment of tear film osmolarity using the TearLab
Sebbag L; Park SA; Kass PH; Maggs DJ; Attar M; Murphy CJ
Vet Ophthalmol; 2017 Jul; 20(4):357-364. PubMed ID: 27761982
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A.
Brignole F; Pisella PJ; De Saint Jean M; Goldschild M; Goguel A; Baudouin C
Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):90-5. PubMed ID: 11133852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
